355 related articles for article (PubMed ID: 21543343)
1. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis.
Burn J; Bishop DT; Chapman PD; Elliott F; Bertario L; Dunlop MG; Eccles D; Ellis A; Evans DG; Fodde R; Maher ER; Möslein G; Vasen HF; Coaker J; Phillips RK; Bülow S; Mathers JC;
Cancer Prev Res (Phila); 2011 May; 4(5):655-65. PubMed ID: 21543343
[TBL] [Abstract][Full Text] [Related]
2. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).
Burn J; Mathers J; Bishop DT
Recent Results Cancer Res; 2013; 191():157-83. PubMed ID: 22893205
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
[TBL] [Abstract][Full Text] [Related]
4. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
6. The protocol for a European double-blind trial of aspirin and resistant starch in familial adenomatous polyposis: the CAPP study. Concerted Action Polyposis Prevention.
Burn J; Chapman PD; Mathers J; Bertario L; Bishop DT; Bülow S; Cummings J; Phillips R; Vasen H
Eur J Cancer; 1995; 31A(7-8):1385-6. PubMed ID: 7577057
[No Abstract] [Full Text] [Related]
7. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
Trials; 2013 Jul; 14():237. PubMed ID: 23895505
[TBL] [Abstract][Full Text] [Related]
8. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
Ishikawa H; Wakabayashi K; Suzuki S; Mutoh M; Hirata K; Nakamura T; Takeyama I; Kawano A; Gondo N; Abe T; Tokudome S; Goto C; Matsuura N; Sakai T
Cancer Med; 2013 Feb; 2(1):50-6. PubMed ID: 24133627
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention in Lynch syndrome.
Burn J; Mathers JC; Bishop DT
Fam Cancer; 2013 Dec; 12(4):707-18. PubMed ID: 23880960
[TBL] [Abstract][Full Text] [Related]
10. Can resistant starch and/or aspirin prevent the development of colonic neoplasia? The Concerted Action Polyp Prevention (CAPP) 1 Study.
Mathers JC; Mickleburgh I; Chapman PC; Bishop DT; Burn J;
Proc Nutr Soc; 2003 Feb; 62(1):51-7. PubMed ID: 12740057
[TBL] [Abstract][Full Text] [Related]
11. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
12. Primary chemoprevention of familial adenomatous polyposis with sulindac.
Giardiello FM; Yang VW; Hylind LM; Krush AJ; Petersen GM; Trimbath JD; Piantadosi S; Garrett E; Geiman DE; Hubbard W; Offerhaus GJ; Hamilton SR
N Engl J Med; 2002 Apr; 346(14):1054-9. PubMed ID: 11932472
[TBL] [Abstract][Full Text] [Related]
13. Aspirin and familial adenomatous polyposis: coming full circle.
Chan AT
Cancer Prev Res (Phila); 2011 May; 4(5):623-7. PubMed ID: 21543340
[TBL] [Abstract][Full Text] [Related]
14. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial.
Burn J; Gerdes AM; Macrae F; Mecklin JP; Moeslein G; Olschwang S; Eccles D; Evans DG; Maher ER; Bertario L; Bisgaard ML; Dunlop MG; Ho JW; Hodgson SV; Lindblom A; Lubinski J; Morrison PJ; Murday V; Ramesar R; Side L; Scott RJ; Thomas HJ; Vasen HF; Barker G; Crawford G; Elliott F; Movahedi M; Pylvanainen K; Wijnen JT; Fodde R; Lynch HT; Mathers JC; Bishop DT;
Lancet; 2011 Dec; 378(9809):2081-7. PubMed ID: 22036019
[TBL] [Abstract][Full Text] [Related]
15. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.
Asano TK; McLeod RS
Cochrane Database Syst Rev; 2004; 2004(2):CD004079. PubMed ID: 15106236
[TBL] [Abstract][Full Text] [Related]
16. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
[TBL] [Abstract][Full Text] [Related]
17. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis.
West NJ; Clark SK; Phillips RK; Hutchinson JM; Leicester RJ; Belluzzi A; Hull MA
Gut; 2010 Jul; 59(7):918-25. PubMed ID: 20348368
[TBL] [Abstract][Full Text] [Related]
18. Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months.
Williamson SL; Kartheuser A; Coaker J; Kooshkghazi MD; Fodde R; Burn J; Mathers JC
Carcinogenesis; 1999 May; 20(5):805-10. PubMed ID: 10334197
[TBL] [Abstract][Full Text] [Related]
19. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac.
Keller JJ; Offerhaus GJ; Polak M; Goodman SN; Zahurak ML; Hylind LM; Hamilton SR; Giardiello FM
Gut; 1999 Dec; 45(6):822-8. PubMed ID: 10562579
[TBL] [Abstract][Full Text] [Related]
20. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
